...Number of Study Participants With Grade 3 or 4 Treatment-related Toxicity`Cumulative Incidence of Sustained Objective Responses`Progression-free Survival`Change in Perfusion Ratio Between the Baseline and Day 15 Brain Imaging`Change in Diffusion Ratio Between the Baseline and Day 15 Brain Image`Association of Log-transformed Tumor Volume Based on FLAIR With Progression-free Survival (PFS) Using Hazard Ratio Estimates`Association of Log-transformed Tumor Enhancing Volume With Progression-free Survival (PFS) Using Hazard Ratio Estimates`Association of Log-transformed Volume of Cystic Necrosis With Progression-free Survival (PFS) Using Hazard Ratio Estimates`Association of Log-transformed Tumor Diffusion Ratio With Progression-free Survival (PFS) Using Hazard Ratio Estimates`Association of Log-transformed Tumor Perfusion Ratio With Progression-free Survival (PFS) Using Hazard Ratio Estimates`Volume of Distribution`Systemic Clearance`Terminal Half-life`Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline to Day-15`Descriptive Statistics for the Changes in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) Concurrently Measured With the Changes in Perfusion From Magnetic Resonance Imaging`Descriptive Statistics for the Change of Perfusion in Magnetic Resonance Imaging Concurrently Measured With the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC)`Correlation of the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline With the Change in Perfusion From Magnetic Resonance Imaging`Number of Patients With High Hypoxia Inducible Factor-2alpha Expression at Baseline`Number of Patients With High Carbonic Anhydrase 9 Expression at Baseline`Number of Patients With High VEGF-A Expression at Baseline`Number of Patients With High VEGF-R2 Expression at Baseline`Progression-free Survival Hazard Ratio by Hypoxia Inducible Factor-2alpha Expression`Progression-free Survival Hazard Ratio by Carbonic Anhydrase 9 (CA9) Expression`Progression-free Survival Hazard Ratio by VEGF-A Expression`Progression-free Survival Hazard Ratio by VEGF-R2 Expression...

We reanalyzed the gene expression data of xenografts of tumors of bevacizumab-resistant glioblastoma multiforme (GBM) patients…The survival analysis showed that three upregulated hub genes (CXCL8, VEGFA, and IDH1) were associated with poor survival. The results predict that these hub genes associated with the GBM resistance to bevacizumab may be potential therapeutic targets or can be biomarkers of the anti-VEGF resistance of GBM.